Teva Launches First Inhalable Antipsychotic Drug in U.S.

Adasuve reduces agitation in adults with schizophrenia or bipolar I disorder.

Send in e-mailSend in e-mail

Teva Pharmaceutical Industries is launching the first orally inhaled medicine for treating agitation associated with adult schizophrenia or bipolar I disorder in the United States, the company announced on Monday.

Adasuve is administered with an innovative handheld aerosol device developed by Alexza Pharmaceuticals. Previous treatment options for the condition were limited to pills or injections, sometimes requiring the use of restraints.

Teva acquired the rights to the drug, the first of the new therapeutic entities that are a major part of the company’s growth strategy, last May for $40 million up-front and $195 million in milestone payments.

As many as five million patients with bipolar I disorder or schizophrenia in the U.S. experience and seek treatment for agitation episodes.

The drug's efficacy was demonstrated in two clinical trials on acute agitation, one associated with schizophrenia and the other with bipolar I disorder. Adasuve showed significant reduction in agitation at two hours, with an effect seen as early as ten minutes post-dose.

"The availability of orally inhaled Adasuve provides a rapid onset of action that quickly improves symptoms for patients and gives providers in enrolled hospitals another treatment choice," said Michael McHugh, vice president and general manager, Teva Select Brands and Teva Women's Health.

McHugh said the drug's launch was part of the company's "ongoing commitment to enhancing patient care and bringing new therapies and delivery systems to the market that fit within our areas of expertise."

Teva's headquarters in Jerusalem.Credit: Bloomberg

Click the alert icon to follow topics:



Automatic approval of subscriber comments.
From $1 for the first month

Already signed up? LOG IN


Charles Lindbergh addressing an America First Committee rally on October 3, 1941.

Ken Burns’ Brilliant ‘The U.S. and the Holocaust’ Has Only One Problem

The projected rise in sea level on a beach in Haifa over the next 30 years.

Facing Rapid Rise in Sea Levels, Israel Could Lose Large Parts of Its Coastline by 2050

Tal Dilian.

As Israel Reins in Its Cyberarms Industry, an Ex-intel Officer Is Building a New Empire

Queen Elizabeth II, King Charles III and a British synagogue.

How the Queen’s Death Changes British Jewry’s Most Distinctive Prayer

Newly appointed Israeli ambassador to Chile, Gil Artzyeli, poses for a group picture alongside Rabbi Yonatan Szewkis, Chilean deputy Helia Molina and Gerardo Gorodischer, during a religious ceremony in a synagogue in Vina del Mar, Chile last week.

Chile Community Leaders 'Horrified' by Treatment of Israeli Envoy

Queen Elizabeth attends a ceremony at Windsor Castle, in June 2021.

Over 120 Countries, but Never Israel: Queen Elizabeth II's Unofficial Boycott